Inhibiting the PD-1/PD-L1 pathway can significantly boost the infiltration of CD4+ and CD8+ T cells in tumor cells, and effectively regulate the expression of a range of immune-related factors such as IL-2, IFN-γ, and TNF-α, thereby strengthening the body's anti-tumor immune function. Here, CD4 is linked to neoplasm.